SLXN Silexion Therapeutics: רווח למניה ב-12 החודשים האחרונים

The prospects of Silexion Therapeutics Corp (SLXN) depend on the outcomes of RNA drug trials, which necessitates strict capital management. The company plans to generate revenue from pancreatic cancer therapy via siRNA technologies. The YoY change in EPS on a rolling 12-month basis helps determine the real value of assets, where the current figure is 37.10. The success of a single molecule would ensure global reach and colossal profits with minimal expenditures.
SLXN (Silexion): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator measures the dynamics of net earnings per share over a rolling year, reflecting the market's revaluation of business profitability. By analyzing the 12-month YoY earnings per share growth rate, an investor assesses the efficiency of corporate income capitalization. For Silexion Therapeutics Corp (SLXN), this metric is critical, as oncology RNA therapy is currently in the clinical testing stage. The future sustainability of the company depends directly on the commercialization of its platforms. High volatility on the chart underscores the risks associated with early-stage development.